Ignite Creation Date:
2024-05-05 @ 11:37 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00091585
Status:
COMPLETED
Last Update Posted:
2007-05-10
First Post:
2004-09-10
Brief Title:
Initial Safety Assessment of SNS-595 for the Treatment of Solid Tumors
Sponsor:
Sunesis Pharmaceuticals
Organization:
Sunesis Pharmaceuticals
Study Overview
Official Title:
Phase I Open-Label Multicenter Dose-Escalation Clinical Study of the Initial Safety and Pharmacokinetic Profiles of Intravenous Administration of SNS-595 in Patients With Advanced Malignancies
Status:
COMPLETED
Status Verified Date:
2007-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine whether SNS-595 given intravenously once every 3 weeks is safe
Detailed Description:
Other objectives of this study include measuring pharmacokinetics how long the drug can be measured in the blood and determining the dose and dose schedule for the next phase of studies with SNS-595
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None